B Cell Maturation Antigen BCMA Targeted Drug Therapy Market Insight 2026
BCMA Drug Market expected To surpass USD 4 Billion By 2026 Says Kuick Research
Delhi, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Delhi,India: Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs
- Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
Multiple myeloma is the most frequently occurring hematological malignancy which is characterized by the uncontrolled growth of plasma cells in bone marrow. The introduction of proteasome inhibitors and immunomodulatory drugs has significantly improved the survival rates in patients, but most of the patients relapse due to development of drug resistance. The increased understanding about the biology of multiple myeloma has led to identification of other potential therapeutic targets which can overcome the limitations of already approved therapies.
Genetic analyses have shown the expression of B-cell maturation antigen (BCMA) on all multiple myeloma cancer cell lines. BCMA or tumor necrosis factor receptor superfamily member is transmembrane protein which has critical role in the maturation and differentiation of B-cells into plasma cells. Presently, two BCMA targeted therapies including Belantamab mafodotin (Blenrep) and Idecabtagene Vicleucel (Abecma) have been approved as monotherapy in patients with relapsed or refractory multiple myeloma. Blenrep is antibody drug conjugate which consists of anti-BCMA IgG1 monoclonal antibody conjugated to monomethyl auristatin F via non-cleavable linker. In contrast, Abecma is second generation BCMA targeted CAR T-cell incorporating a single chain variable fragment, a 4-1BB co-stimulating domain and a CD3Zeta signaling domain, inducing cytotoxicity against MM cells independently of BCMA expression or soluble BCMA.
The introduction of BCMA targeted therapy is expected to be game change in multiple myeloma as it provide new approach to treat myeloma patients especially who have been heavily pretreated. The clinical studies have shown that BCMA targeted therapy significantly enhance the overall survival rate and progression free survival whereas and is associated with less and manageable adverse events. As per our report analysis, both the drugs will show high adoption rates in the global market and are expected to constitute a significant share in multiple myeloma therapeutics market in forthcoming years.
Apart from chimeric antigen receptor (CAR) T-cell therapy and antibody drug conjugates, researchers have also developed several bispecific antibodies and trispecific T-cell engager targeting BCMA. The advent of multi-specific antibodies increases the specificity and targetability, thereby enhancing the T-cell mediated lysis. In addition, these molecules have high penetration in the cell membrane and have easy synthesis owing to their small size. Several potential candidates including AMG 420, CC-93269, REGN5458, TNB383B, AMG 701, and others are present in preclinical and clinical development, which are expected to enter the market in forthcoming years.
Several ongoing clinical trials are also evaluating the role of drug as monotherapy or in combinational therapy for the treatment of relapsed plasmablastic lymphoma, anaplastic lymphoma kinase, and several other subsets of multiple myeloma which will further drive its growth in market. For instance, Abecma is being evaluated in combination with other modalities including pembrolizumab, dexamethasone, and other chemotherapeutic agents which aim to enhance the efficacy of the treatment. The market for BCMA targeted therapy is highly competitive and consists of several key players including Novartis, Juno Therapeutics, Eureka Therapeutics, Amgen, Celgene, and others. The major players in the market have adopted strategic alliances to secure their position in market.
The global BCMA targeted therapy market is estimated to surpass US$ 4 Billion by 2026. The high growth rates in the market are mainly attributed to increase in geriatric population and subsequent rise in prevalence of cancer. As per our analysis, forecast period will see rapid influx of BCMA targeted drugs in management of wide range of cancers which will further propel the growth of market. US held the major share in the market owing to high adoption rates of novel therapies, favorable reimbursement policies, and presence of pharmaceutical giants which actively indulge in research and development sector.
Contact:
Neeraj Chawla
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com
Contact: Neeraj Chawla Research Head +91-981410366 neeraj@kuickresearch.com https://www.kuickresearch.com
